THE INTERPLAY BETWEEN C-MYCONCOGENE EXPRESSION AND CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR, ITS ANTAGONIST RECEPTOR, FUNS-LIKE TYROSINE KINASE 1 IN DIFFUSE LARGE B CELL LYMPHOMA: RELATIONSHIP TO PATIENT OUTCOME
Azim Ali, A., S, A., M, S., M, M., H, E., K, Z., Elsherbeny, M. (2006). THE INTERPLAY BETWEEN C-MYCONCOGENE EXPRESSION AND CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR, ITS ANTAGONIST RECEPTOR, FUNS-LIKE TYROSINE KINASE 1 IN DIFFUSE LARGE B CELL LYMPHOMA: RELATIONSHIP TO PATIENT OUTCOME. EKB Journal Management System, 25(1), 29-37. doi: 10.21608/ejsur.2006.373099
Abdel Azim Ali; Aref S; Sakrana M; Mabed M; El Askalany H; Zalata K; M Elsherbeny. "THE INTERPLAY BETWEEN C-MYCONCOGENE EXPRESSION AND CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR, ITS ANTAGONIST RECEPTOR, FUNS-LIKE TYROSINE KINASE 1 IN DIFFUSE LARGE B CELL LYMPHOMA: RELATIONSHIP TO PATIENT OUTCOME". EKB Journal Management System, 25, 1, 2006, 29-37. doi: 10.21608/ejsur.2006.373099
Azim Ali, A., S, A., M, S., M, M., H, E., K, Z., Elsherbeny, M. (2006). 'THE INTERPLAY BETWEEN C-MYCONCOGENE EXPRESSION AND CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR, ITS ANTAGONIST RECEPTOR, FUNS-LIKE TYROSINE KINASE 1 IN DIFFUSE LARGE B CELL LYMPHOMA: RELATIONSHIP TO PATIENT OUTCOME', EKB Journal Management System, 25(1), pp. 29-37. doi: 10.21608/ejsur.2006.373099
Azim Ali, A., S, A., M, S., M, M., H, E., K, Z., Elsherbeny, M. THE INTERPLAY BETWEEN C-MYCONCOGENE EXPRESSION AND CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR, ITS ANTAGONIST RECEPTOR, FUNS-LIKE TYROSINE KINASE 1 IN DIFFUSE LARGE B CELL LYMPHOMA: RELATIONSHIP TO PATIENT OUTCOME. EKB Journal Management System, 2006; 25(1): 29-37. doi: 10.21608/ejsur.2006.373099

THE INTERPLAY BETWEEN C-MYCONCOGENE EXPRESSION AND CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR, ITS ANTAGONIST RECEPTOR, FUNS-LIKE TYROSINE KINASE 1 IN DIFFUSE LARGE B CELL LYMPHOMA: RELATIONSHIP TO PATIENT OUTCOME

The Egyptian Journal of Surgery
Volume 25, Issue 1, January 2006, Page 29-37  XML PDF (178.4 K)
Document Type: Original Article
DOI: 10.21608/ejsur.2006.373099
View on SCiNiTO View on SCiNiTO
Authors
Abdel Azim Ali* 1; Aref S2; Sakrana M3; Mabed M3; El Askalany H3; Zalata K4; M Elsherbeny5
1General Surgery Department, Faculty of Medicine, Mansoura University-Egypt
2Hematology Unit, Faculty of Medicine, Mansoura University-Egypt
3Internal Medicine Department, Faculty of Medicine, Mansoura University-Egypt
4Pathology Department, Faculty of Medicine, Mansoura University-Egypt
5Cancer institute, Faculty of Medicine, Mansoura University-Egypt
Abstract
Aim: is to assess the relation between c-Myc oncogene expression and angiogenic factors namely vascular endothelial growth factor (VEGF), funs-like tyrosine kinase 1(Flt-1) in patients with diffuse large B cell lymphoma (DLBCL) and their impact on the patient outcome. 
Methods: Forty Five DLBCL patients beside 10 normal controls were included. c-Myc oncoprotein was assessed by 
immunohistochemistry and sVEGF, and sFlt-1 were assessed by immunosorbent assay. 
Results: c-Myc over-expression was detected in 66.6% of DLBCL. The DLBCL patient group with positive c-Myc overexpression showed significantly higher sVEGF and significantly decreased sFlt-1 as compared to group with negative c-Myc over-expression (P=0.000, 0.009 respectively). sVEGF was positively correlated to sLDH and .v./32 microglobulin (r =0.6, p=0.000, r =0.69, P= 0.000) respectively. The non-survived DLBCL group showed significantly higher expression of c-Myc , high concentration of sVEGF and lower concentration in sFlt-1 as compared to the living group (P=0.000 for all). 
Conclusion: These findings confirm the in vitro based suggestion that c-Myc over-expression orchestrate the angiogenic 
switch necessary for tumor progression. c-Myc over-expression, elevated sVEGF, and normal sFlt-1 at diagnosis are poor 
prognostic markers in DLBCL patients. 
Keywords
Lymphoid neoplasm; Tumor marker; Prognosis
Statistics
Article View: 75
PDF Download: 31